Live Breaking News & Updates on Post Conference Perspectives

Stay updated with breaking news from Post conference perspectives. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care. ....

Post Conference Perspectives Year , Recurrent Endometrial Cancer , Patients With Advanced Endometrial , Floor Backes , Post Conference Perspectives , Endometrial Cancer , Gynecologic Cancers , Endometrial Cancer Treatments , Endometrial Cancer Treatment Updates ,

Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation. ....

Post Conference Perspectives Year , Recurrent Endometrial Cancer , Post Conference Perspectives , Endometrial Cancer , Gynecologic Cancers , Endometrial Cancer Treatments , Endometrial Cancer Treatment Updates ,

Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance. ....

Post Conference Perspectives Year , Recurrent Endometrial Cancer , Atezolizumab Plus Carboplatin , Advanced Endometrial , Post Conference Perspectives , Endometrial Cancer , Gynecologic Cancers , Endometrial Cancer Treatments , Endometrial Cancer Treatment Updates ,

Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial

Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer. ....

Matthew Powell , Post Conference Perspectives Year , Recurrent Endometrial Cancer , Advanced Endometrial Cancer , Floor Backes , Post Conference Perspectives , Endometrial Cancer , Gynecologic Cancers , Endometrial Cancer Treatments , Endometrial Cancer Treatment Updates ,